Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05875961 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
A Phase 1 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 1
- Development phase
- 600
- Enrollment target
NCT05875961 is a Phase 1 study that has completed, run by Seqirus. The registered enrollment target is 600 participants.
The verdict
NCT05875961, a Phase 1 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 600 participants
- Enrollment target
Study Summary
This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2N3 influenza vaccine. Approximately 600 healthy adult subjects are to be randomized into 1 of 6 possible treatment groups with 100 subjects per group, stratified by age group (born after or before 1968). Each subject will receive an influenza vaccine injection on Day 1 and Day 22. Subjects will be followed up for approximately 12 months after the second vaccine injection. The primary immunogenicity analysis is based on the Day 1, Day 8, Day 22, Day 29, and Day 43 serology data. The primary safety analysis is based on solicited local and systemic adverse events (AEs) reported within 10 days after each vaccination, unsolicited AEs reported within 3 weeks after each vaccination, and serious AEs (SAEs), medically attended AEs (MAAEs), AEs leading to withdrawal from the study, and AEs of special interest (AESIs) reported throughout the study.
Interventions
- BIOLOGICAL Low dose A/H2N3c + standard dose MF59
- BIOLOGICAL Intermediate dose A/H2N3c + standard dose MF59
- BIOLOGICAL High dose A/H2N3c + standard dose MF59
- BIOLOGICAL High dose A/H2N3c non-adjuvanted
- BIOLOGICAL Lowest dose A/H2N3c + high dose MF59
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2024-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05875961
The ClinicalTrials.gov registry entry for NCT05875961 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Low dose A/H2N3c + standard dose MF59 is the first listed.
NCT05875961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05875961 about?
NCT05875961 is a clinical study titled "Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults". This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2N3 influenza vaccine. Approximately 600 healthy adult subjects are to be randomized into 1 of 6 possible treatment groups with 100 subjects per group, ...
What is the current status of trial NCT05875961?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 600 participants. The study started on 2023-06-15. Estimated completion is 2024-11-15.
What interventions are being tested in trial NCT05875961?
The interventions under investigation include: Low dose A/H2N3c + standard dose MF59 (BIOLOGICAL), Intermediate dose A/H2N3c + standard dose MF59 (BIOLOGICAL), High dose A/H2N3c + standard dose MF59 (BIOLOGICAL), High dose A/H2N3c non-adjuvanted (BIOLOGICAL), Lowest dose A/H2N3c + high dose MF59 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05875961?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.